Pyruvate dehydrogenase (PDH), the first component of the human pyruvate dehydrogenase complex (PDC), has two isoenzymes, somatic cell-specific PDH1 and testis-specific PDH2 with 87% sequence identity in the α subunit of α 2 β 2 PDH. The presence of functional testis-specific PDH2 is important for sperm cells generating nearly all their energy from carbohydrate via pyruvate oxidation. Kinetic and regulatory properties of recombinant human PDH2 and PDH1 were compared in this study. Site-specific phosphorylation/dephosphorylation of the three phosphorylation sites by four PDH kinases (PDK1-4) and two PDH phosphatases (PDP1-2) were investigated by substituting serines with alanine or glutamate in PDHs. PDH2 was found to be very similar to PDH1 in: (i) specific activities and kinetic parameters as determined by PDC assay; (ii); thermostability at 37 0 C; (iii) mechanism of inactivation by phosphorylation of three sites and (iv) phosphorylation of sites 1 and 2 by PDK3. In contrast, the differences for PDH2 were indicated by: (i) 2.4-fold increase in binding affinity for the PDH-binding domain of dihydrolipoamide acetyltransferase as measured by surface plasmon resonance; (ii) possible involvement of S264 (site 1) of PDH2 in catalysis as evident by its kinetic behavior; and (iii) lower activities of PDK1, PDK2, PDK4 as well as PDP1 and PDP2 towards PDH2. These differences between PDH2 and PDH1 are less than expected from substitution of 47 amino acids in each PDH2 α subunit. The multiple substitutions may have compensated for any drastic alterations in PDH2 structure thereby preserving its kinetic and regulatory characteristics largely similar to that of PDH1.
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Mammalian pyruvate dehydrogenase complex (PDC)
1 plays a central role in glucose oxidation by catalyzing the oxidative decarboxylation of pyruvic acid with formation of carbon dioxide, acetyl-CoA, NADH and H + (for reviews see (1) (2) (3) . PDC is composed of multiple copies of three catalytic components: (i) pyruvate dehydrogenase (PDH) catalyzing the decarboxylation of pyruvate and reductive acetylation of the lipoyl moieties of dihydrolipoamide acetyltransferase (E2); (ii) E2 transferring acetyl moiety to CoA; (iii) and dihydrolipoamide dehydrogenase (E3) reoxidizing the reduced lipoyl moieties of E2 with the reduction of NAD + to NADH (1) (2) (3) . Forty eightsixty subunits of E2 and 12 subunits of E3-binding protein (BP), a non-catalytic component of mammalian PDC, form the central core of the multienzyme PDC, which binds 20-30 tetramers of PDH, 6-12 dimers of E3 and two regulatory enzymes, 1-2 copies of pyruvate dehydrogenase kinase (PDK) and 2-3 copies of pyruvate dehydrogenase phosphatase (PDP) (4, 5) . PDK and PDP provide the finely tuned regulation of activity of PDC through reversible phosphorylationdephosphorylation of PDH (and hence PDC) depending on cellular demand for glucose oxidation.
Mammalian PDH is tetramer consisting of two α and two β subunits. The human PDHα subunit is encoded by two genes: PDHA1 (located on chromosome X) is expressed in somatic cells and PDHA2 (located on chromosome 4) is expressed in testis only (6, 7) . The PDHβ subunit is encoded by PDHB (localized on chromosome 3) and is common to PDH in somatic and testicular cells (8) . A transcriptional switch from PDHA1 to PDHA2 occurs during the first meiotic prophase of spermatogenesis (9) . As a result human PDH is present as two isoenzymes: somatic-specific, PDH1 and testis-specific, PDH2. PDH2 functions during spermatogenesis and in the male germ cells (9) .
Mammalian PDH1 and PDH2 are heterotetramers (α 2 β 2 ), and the three phosphorylation sites [Ser264 (site 1), Ser271 (site 2), and Ser203 (site 3)] are present on the α subunit of each isoenzyme. Human PDH1 has been extensively investigated for its site-specific regulation (10) (11) (12) (13) . Phosphorylation of each of the three sites in human PDH1 by PDKs results in inactivation of PDH1 (and hence PDC); however, the rates of phosphorylation and inactivation are site-specific (10) . Additionally site-directed modification of each of the three sites in PDH1 affects binding of the cofactor (thiamin pyrophosphate, TPP) and two substrates (pyruvate and lipoyl moieties of E2) in the active site in a site-specific manner (11) . Four PDK isoenzymes are present in mammalian tissues with different tissue-specific distributions, kinetic parameters, and regulation (14, 15) . PDK isoenzymes have different specificity towards the three phosphorylation sites of PDH1 (12, 13) . All four PDKs phosphorylate sites 1 and 2 with different rates (PDK2 has highest activity towards site 1 and PDK3 towards site 2), however, site 3 is phosphorylated by PDK1 only. Two of the PDK isoenzymes (PDK4 and to a lesser extent PDK2) have been implicated in regulation of PDC in certain tissues during starvation, diabetes and hyperthyroidism (16, 17) .
Two isoenzymes of the catalytic subunit of PDPs, PDP1 and PDP2, show different tissue distributions, catalytic and regulatory properties (15, 18) . PDP1 and PDP2 was found to be downregulated during starvation and diabetes adding to PDC inhibition by the up-regulation of PDK2 and PDK4 (19, 20) . Site 1 is phosphorylated faster than the other sites, however, in PDC all three sites could potentially be phosphorylated resulting in the hyperphosphorylation. At the same time PDP1 and PDP2 dephosphorylate site 1 slower than the other sites (21) . This would slow down the reactivation as reactivation of PDC requires dephosphorylation of all the three sites.
The amino acid sequence identity between the α subunits of somatic PDH1 and testis-specific PDH2 is about 87%, and this may result in the differences in the catalytic properties and regulation of these two human PDH isoenzymes. Single missense mutations in the PDH1α subunit were shown to result in reduction in catalytic activity and caused severe lactic acidosis and neurological dysfunction and even early death in the PDH1-deficient patients (22) . Human PDH1 and rat PDH2 were expressed previously and were shown to have different specific activities and the ability to be phosphorylated by PDK1 and PDK2 (23) . Since four PDK isoenzymes are present in mammalian tissues with different tissue distributions and site-specificity for the three phosphorylation sites of human PDH1 and since PDK3 is expressed predominantly in the testis (14) , it was of interest to examine the interaction between PDK3 and PDH2 expressed only in postmeiotic cells in the testis.
In this study we have examined the catalytic parameters of human PDH2 and compared them with that of PDH1 as well as investigated the mechanism of inactivation by phosphorylation of each of the three sites of PDH2 and the specificity of the four PDK isoenzymes and two PDP isoenzymes for the three phosphorylation sites of PDH2. Surprisingly our findings show that, the kinetic characteristics of PDH2 having only 87% identity in the sequence with PDH1 are similar to that of PDH1 and its regulation by phosphorylation is also not very different from that of PDH1.
Experimental Procedures
Materials -All chemicals were of high purity and were obtained from Sigma (St. Louis, MO). Restriction and DNA modifying enzymes were purchased from Promega (Madison, WI). Quick Change site-directed mutagenesis kit was from Stratagene (La Jolla, CA). The oligonucleotides used for construction of expression vectors and site-directed mutagenesis were synthesized by Invitrogen (Carlsbad, CA). The protein assay reagent was from BioRad (Hercules, CA). [γ-32 P]ATP was obtained from MP Biomedicals (Irvine, CA). Ni-nitrilotriacetate-agarose (Ni-NTA-agarose) was from Qiagen (Valencia, CA). pPDK1, pPDK2, pPDK3, pPDK4, pPDP1, and pPDP2 expression vectors and Escherichia coli BL21 with pPDHE2/E3BP were generously provided by Dr. Robert A. Harris of Indiana University School of Medicine, Indianapolis, IN. Construction of Expression Vectors and Sitedirected Mutagenesis -To construct the PDH2 coexpression vector, PDHA2 cDNA was subcloned into NheI and EcoRI restriction sites of pET-28b. The resulting vector, pET-28b-PDHA2, was digested with SalI and PvuI and ligated with pET-28b-PDHB (with PDHB cDNA subcloned into NcoI and XhoI restriction sites and introduced SalI restriction site) digested with the same restriction enzymes. The final construct (pET-28b-PDHA2/PDHB) contained the PDHA2 cDNA and PDHB cDNA. His-tag was added to the Nterminus of the PDH2 sequence for affinity purification with Ni-NTA-agarose column. pET28b-PDHA1/PDHB was constructed in the same way as pET-28b-PDHA2/PDHB to compare kinetic parameters of PDH1 and PDH2 having exactly the same extension at N-termini.
Several mutants of the three phosphorylation sites on the α subunit were made: PDH2-S1A, PDH2-S2A, PDH2-S3A [with Ser264 (site 1), Ser271 (site 2) and Ser203 (site 3,) respectively, of PDH2 substituted with alanine,] and PDH2-S1E, PDH2-S2E, PDH2-S3E (with Ser264, Ser271 and Ser203, respectively, of PDH2 substituted with glutamate). Site-directed mutagenesis was performed using Quick-change site-directed mutagenesis kit (Stratagene, La Jolla, CA). Mutants having double mutations of serines to alanines were constructed in the same way to have only site 1 (PDH2-S2A/S3A), site 2 (PDH2-S1A/S3A) and site 3 (PDH2-S1A/S2A) available for phosphorylation. Similar single and double mutants of PDH1 were constructed previously (10) .
The expression vector (pET-28b-L2S) for the E2 fragment (L2S) containing the second lipoyl domain, the second hinge region, the PDHbinding domain (also known as subunit-binding domain) and the third hinge region of E2 was constructed. cDNA encoding for residues 128-330 of human E2 was subcloned into NheI and XhoI restriction sites of pET-28b. The pET-28b-L2S construct encodes for L2S protein with His-tag at the N-terminus for affinity purification with Ni-NTA-agarose column. The complete coding sequences of all constructs were verified by DNA sequencing (Roswell Park Cancer Institute, Buffalo, NY).
Protein
Expression and Purification -Recombinant PDH2, PDH2 mutants, PDH1 and PDH1 mutants were overexpressed in E. coli BL21 and purified from M15 pQE-9-E1α/E1β using Ni-NTA-agarose chromatography similarly to the previously reported purification scheme for PDH1 (24, 25) with minor modifications: proteins were loaded on the Ni-NTA-agarose column which was washed with 75 mM imidazole (and not with 50 mM imidazole as for PDH1) overnight followed by elution with 75-250 mM imidazole gradient in 50 mM potassium phosphate buffer, pH 7.5. After elution proteins were concentrated and dialyzed against 50 mM potassium phosphate buffer, pH 7.0 with 0.5 mM dithiothreitol. Recombinant E2-BP, E3, and PDKs were overexpressed in E. coli and purified as described elsewhere (11) . PDP1 and PDP2 were purified using a protocol similar to that described for PDKs. Recombinant human L2S was overexpressed in E. coli BL21 and purified by Ni-NTA-agarose affinity chromatography. L2S was eluted with 25-250 mM imidazole gradient in 50 mM potassium phosphate buffer, pH 7.5, concentrated and dialyzed against 50 mM potassium phosphate buffer, pH 7.5 with 0.5 mM dithiothreitol.
The enzyme preparations had purity of 90-96% as judged by densitometry of SDSpolyacrylamide gels (results not shown). Protein was measured by the Bradford method using bovine serum albumin as a standard (26) . Kinetic Analysis -Activities of PDHs (both PDH2 and PDH1) were determined by PDC assay by the formation of NADH during overall PDC reaction after reconstitution of PDHs with E2-BP and E3 into PDC as described previously (11) . The apparent K m values for TPP and pyruvate were determined by varying the concentrations of TPP from 0.05 to 500 and the concentrations of pyruvate from 5 to 1000 μM. To determine stability of PDH2 compared to PDH1, PDH proteins were incubated at 37 0 C in two ways: (i) PDH2 or PDH1 (12 μg) was reconstituted with E2-BP (24 μg ) and E3 (24 μg) in 50 mM potassium phosphate buffer, pH 7.5 to the total volume of 100 μl or (ii) PDH2 or PDH1 (20 μg) only was incubated in 50 mM potassium phosphate buffer, pH 7.0 with a total volume 100 μl. Aliquots were taken to measure PDC activity (PDH2 or PDH1 incubated alone was reconstituted into PDC prior to performing PDC assay). One unit of enzyme activity is defined as 1 μmol of product formed per min at 37 0 C. Correlation coefficients in all kinetic experiments were at least 95%. Surface Plasmon Resonance -Surface plasmon resonance (SPR) measurements were performed on BIAcore X instrument. L2S was immobilized on the CM5 chip through the lipoyl moieties by a surface thiol coupling method. For this purpose the following reagents were applied on the sensor chip surface at a flow rate of 5 μl/min: 35 μl of the 1/1 mixture of 100 mM N-hydroxysuccinimide and 100 mM N-ethyl-N'-[3-(dimethylamino)propyl]carbodiimide hydrochloride to activate the surface; 15 μl of 40 mM cystamine in 100 mM sodium borate buffer, pH 8.5 to introduce disulfides; 20 μl of 100 mM dithioerythritol in 100 mM sodium borate buffer, pH 8.5 to reduce disulfides to thiols; 60 μl of L2S (50 μg/ml) in 10 mM CH3COONa, pH 4.0 to couple the ligand (L2S); and 35 μl of 20 mM 2-(2-pyridinyldithio)ethaneamine hydrochloride in 100 mM sodium borate buffer, pH 4.3, 1 M NaCl to deactivate excess thiol (27) . PDH2 or PDH1 in the concentration range: 0-3000 nM was injected to interact with the sensor surface at 10 μl/min in HBS buffer (10 mM HEPES, pH 7.4, 15 mM NaCl, 3 mM EDTA and 0.005% surfactant P20). Duplicate runs were performed for each concentration. The association phase during PDH2 or PDH1 flow was 2 min followed by the dissociation phase with HBS buffer flow for 3 min. Regeneration of the surface with bound ligand (L2S) was not required. The reference cell on the surface of which L2S was not immobilized was used to subtract non-specific binding. Experimental data were analyzed with BIAevaluation software to calculate the association and dissociation rate constants and the equilibrium dissociation constant.
Determination of PDKs Activity and Kinetic
Parameters -Activities of PDKs were determined with double mutants of PDH2 and PDH1 (having only site 1, 2 or 3 available for phosphorylation) either after reconstitution in PDC or in a free form as described previously (13) . Activities of PDKs were determined in phosphate buffer (20 mM potassium phosphate buffer, pH 7.0, 0.1 mM EDTA, 1 mM MgCl 2 , 2 mM dithiothreitol). ATP was used in the following concentrations: 300 μM for PDK1, PDK2 and PDK4 and 100 μM for PDK3 as described previously (13) . Activities of PDKs towards PDH in reconstituted PDC were determined with the oxidized lipoyl moieties of E2 [in the presence of NAD + /NADH=200/1 (796 μM/4 μM) with 50 μM CoA]. Triplicate or quadruplicate measurements were averaged for all the experimental data points. Negative controls (without PDK) were subtracted. One unit of PDK activity is defined as 1 μmol of 32 P incorporated into PDH per min at 30 0 C. Correlation coefficients in all experiments were at least 95%. Determination of PDP Activity -To determine activities of PDP1 and PDP2, PDH2 and PDH1 double mutants with site 1, 2 or 3 only available for phosphorylation were phosphorylated by PDK2 (for sites 1 and 2) or PDK1 (for site 3) as described above. ATP was depleted by incubating with 10 mM glucose and 15 μg of yeast hexokinase for 30 min. MgCl 2 and CaCl 2 were added to the phosphorylated PDHs to final concentrations of 10 mM and 100 μM, respectively. Reaction were started by the addition of 0.2 μg of PDP. Aliquots were removed every min during 10 min period and applied on the paper discs presoaked with 10% trichloroacetic acid with 10 mM pyrophosphate. Discs were washed with 10% trichloroacetic acid and ethanol, dried and counted as described for the determination of PDKs activities (13) . Only linear rates of the reactions were used for calculations. Negative controls (without PDP) were subtracted from all the data points. One unit of PDP activity defined as 1 μmol of 32 P released from 32 P-PDH per min at 30 0 C. Correlation coefficients were at least 90%.
RESULTS

Sequence Comparison between α Subunis of
PDH2 and PDH1 - Figure 1 shows the alignment of the sequences of the α subunits of human PDH2 and PDH1. Their sequences have 87% identity and 93% homology. The PDH2 and PDH1 isoenzymes have highly conserved sequences (residues 166-196) in the TPP-motif region [sequence of residues conserved within the TPP-requiring enzymes, residues of which are involved in the binding of the pyrophosphate moiety of TPP through the divalent ion (28, 29) ]. Sequences surrounding the phosphorylation sites are also conserved. However, 47 residues are different in the α subunit of PDH2 compared to PDH1, 26 of which are non-homologous substitutions (Fig. 1) . Two residues of PDH1, i.e. H15 and F176, involved in PDH1 deficiency are replaced in PDH2 by Y15 and A176, respectively. Three proline residues belonging to the C-terminal region of the α subunit of PDH1 (amino acid residues 331-361) are replaced in the PDH2α sequence probably changing the conformation of the C-terminus. The conformation of the Cterminus of PDH1 was shown to be important for the subunit-subunit interactions (30) . Kinetic Analysis of PDH2 -Activities of highly purified recombinant human PDHs were determined using PDC assay measuring the overall reaction of PDH after reconstituting with E2-BP and E3. PDH2 and PDH1 had similar specific activities: 24.6 ± 0.2 U/mg for PDH2 and 25.9 ± 0.3 U/mg for PDH1. The wild-type PDH2 had k cat and K m for TPP similar to that of the wild-type PDH1; however, K m for pyruvate was less for PDH2 (55% of that of PDH1) ( Table 1 ). The kinetic parameters of two PDH isoenzymes are not significantly different. Figure 2 shows the activities of phosphorylation site-specific mutants of PDH2 in the PDC assay system. Similar to PDH1, glutamate substitution of the first phosphorylation site (PDH2-S1E) resulted in the complete loss of PDH2 activity. The reductive acetylation is the rate-limiting step in PDH reaction and the absence of PDH2 activity determined in PDC assay indicates the effect of modification of site 1 on the reductive acetylation step (31) . As with PDH1, glutamate substitution of site 2 or 3 of PDH2 individually did not mimic the phosphorylationdependent near-complete inactivation; PDH2-S2E and PDH2-S3E had only about 37% and 49% of PDC activity, respectively. Phosphorylation of site 1 (using PDH2-S2A/3A) caused complete inactivation of the enzyme and phosphorylation of sites 2 and 3 resulted in drastic reduction in activity by 96% and 91% for sites 2 (PDH2-S1A/3A) and 3 (PDH2-S1A/2A), respectively (results not shown). Substitution of serine of the site 2 or 3 with alanine individually led to about 40-50% reduction in the PDC activity for both PDH2 and PDH1 [ Fig. 2 and (11)]. However, the PDH2-S1A mutant had very low activity (about 15%) (Fig. 2) compared to the PDH1-S1A mutant (about 58%) (11). PDH2-S1A displayed different behavior than PDH1-S1A during the time course of the reaction, showing a decrease in the rate of reaction with increase in time, indicating inactivation during the reaction. Interestingly, PDH1-S1D mutant displayed earlier a similar kinetic behavior as PDH2-S1A (11) . The different kinetic behaviour of the mutants of site 1 of PDH1 and PDH2 possibly reflects the differences in the active sites and the different role of the serine of site 1 in catalysis of two PDH isoforms.
PDH1 was previously shown to have a lag-phase in the progress curve of the reaction at low concentrations of TPP (about 50-60 sec at 0.05 μM TPP and disappearing at 1 μM TPP) reflecting activation of PDH1 during catalysis at suboptimal concentrations of TPP (32) . k obs (reciprocal of the duration of the lag-phase) depended linearly on TPP concentration. S2A and S3A mutants of PDH1 also displayed the lagphase, while S1A, S2E and S3E mutant PDH1s did not (11) . The wild-type PDH2 and its S2A and S3A mutants had the characteristic lag-phase (60-70 sec at 0.05 μM TPP) whereas the lag-phase was very short (5-20 sec) for the S2E and S3E mutants of PDH2, indicating a possible conformational change caused by glutamate substitution that was similar to PDH1.
Kinetic parameters of site 1 mutants are not reported in this study because PDH2-S1A mutant had a different kinetic behavior and PDH2-S1E had no activity. The kinetic parameters for PDH2 mutants of sites 2 and 3 were determined using the PDC assay (Table 1) . K m for pyruvate was not changed for the PDH2 mutants of sites 2 and 3, and K m for TPP was increased for all the mutants examined. For single substitution of sites 2 and 3 K m for TPP increased more with glutamate than with alanine replacement of the serine residues (about 5.6-fold for PDH2-S2E compared with only about 1.6-fold for PDH2-S2A and about 13.2-fold for PDH2-S3E compared with only about 4.1-fold for PDH2-S3A). As a result the catalytic efficiencies of PDH2-S2E and PDH2-S3E were only about 6% and 4%, respectively of that of the wild-type PDH2.
Possible structural changes due to 47 amino acid substitutions in each α subunit of PDH2 compared to PDH1 could affect its thermostability. To investigate this possibility, the stability of both PDH2 and PDH1 was monitored at 37 0 C (as described in the Experimental Procedures section). Incubation of both PDH proteins at 37 0 C either as reconstituted PDC or in free forms had no effect on their specific activities for up to two hours (results not shown), indicating that PDH2 was as stable as PDH1 at 37 0 C. Substitution of site 1 of PDH2 with glutamate did not affect its interaction with the PDH-binding domain of E2. The equilibrium dissociation constant for PDH2-S1E was 18.9 nM similar to that of the wild-type PDH2 (17.5 nM) (results not shown).
Binding of PDH2 to the PDH-binding Domain of
E2 -Binding of PDH2 and PDH1 with the PDHbinding domain of E2 was investigated by surface plasmon resonance. L2S consisting of the second lipoyl domain, second hinge region, PDH-binding domain and the third hinge region was immobilized on the CM5 chip by a surface thiol coupling method. By using this immobilization approach L2S was bound to the chip through the lipoyl domain leaving the PDH-binding domain available for PDH binding and not affected by immobilization because the two domains of L2S are connected by a flexible hinge region.
Specificity of Four PDK Isoenzymes towards the Three Phosphorylation
Sites of PDH2 -Four PDK isoenzymes have different specificity towards the three phosphorylation sites of PDH1 (13) . In this study we have investigated if PDK isoenzymes phosphorylate the three phosphorylation sites of PDH2 differently than those of PDH1. Figure 4 shows activities of PDK isoenzymes for the three phosphorylation sites of PDH2 and PDH1 when both PDH and PDK were reconstituted in PDC. Double mutants of phosphorylation sites of PDH2 and PDH1, having only site 1 (PDH-S2A/S3A), site 2 (PDH-S1A/S3A) or site 3 (PDH-S1A/S2A) were used for these experiments. PDKs had sitespecificity towards the three phosphorylation sites of PDH2 similar to that towards the three phosphorylation sites of PDH1. PDK2 had the highest activity for site 1, PDK3 had higher activity for site 2 than for site 1 and only PDK1 could phosphorylate site 3. PDK3 is present in testis predominantly and is the only isoenzyme having similar activity for sites 1 and 2 of both PDH2 and PDH1 (92% for site 1 and 80% for site 2 of PDH2 compared with PDH1). Activities of PDK1, PDK2 and PDK4 towards site 1 of PDH1 were about 2-fold higher than for PDH2 and for sites 2 and 3 (PDK1 only) were about 4 to 9-fold higher.
PDKs had even lower activities for the site 1 in PDH2 compared to PDH1 when both PDH2 and PDK were not bound to E2 (Fig. 5 ) (activities of PDKs for PDH2 were 16%, 23%, 64%, and 52% for PDK1, PDK2, PDK3, and PDK4, respectively of that for PDH1). PDK3 had the least difference between activities of free PDH1 and PDH2. Dephosphorylation of PDH2 by PDP Isoenzymes -We have investigated whether PDH2 is dephosphorylated differently than PDH1 by PDP1 and PDP2. Figure 6 shows activities of PDP1 and PDP2 towards three phosphorylation sites of PDH2 and PDH1. Both PDP1 and PDP2 had higher activities towards site 2 than sites 1 and 3 of PDH1 as was reported previously (21) . Similar site-specificity was exerted by both the PDPs towards phosphorylation sites of PDH2. The most significant difference between PDH2 and PDH1 as the substrates for PDPs was that both PDP1 and PDP2 dephosphorylated site 2 of PDH2 less efficiently than PDH1. Activities of both PDP1 and PDP2 for site 2 of PDH2 were about 48% of that of PDH1. PDP1 had similar activity towards sites 1 and 3 of both PDH2 and PDH1. The activity of PDP2 was less (by about 60%) for sites 1 and 3 of PDH2 compared to the corresponding sites of PDH1.
DISCUSSION
Like brain cells, spermatozoa are dependent on PDC activity for hexose oxidation to generate energy and therefore the regulation of PDC is very important in the testis. During spermatogenesis half of the sperm cells (being haploid) do not have X chromosome, and in the remaining half the X chromosome is inactivated. To compensate for the loss of expression of the α subunit of PDH1 (encoded by PDHA1 localized on X chromosome), the α subunit of the testisspecific isoenzyme PDH2 is encoded by the PDHA2 gene localized on human chromosome 4 (7).
PDC deficiency is one of the major genetic disorders that causes congenital lactic acidosis and severely affects the nervous system. Of about 200 reported cases, about 130 patients were shown to have mutations in the PDHA1, only three in the β subunit gene (PDHB) and none reported so far in the PDHA2 gene (33) (34) (35) (36) . Patients with mutations causing complete inactivation of PDH1 probably do not survive in utero. The null mutation of the Pdha1 gene in male mouse embryos results in embryonic lethality (37) . Missense mutations in the PDH1 identified in PDH-deficient patients result in marked reductions in PDH1 catalytic function (33) (34) (35) .
Since 47 amino acid residues of the α subunit of PDH1 are replaced in the α subunit of PDH2 and missense mutations of PDH1 cause significant decrease in PDC activity, one would expect drastic changes in the kinetic characteristics of the testisspecific PDH2 isoenzyme compared to somaticspecific isoenzyme. However, this is not the case. In a previous report the recombinant rat α subunit of PDH2 (having 78% identity with human α subunit of PDH2) was coexpressed with recombinant human β subunit and activity of PDH2 was measured using the 2,6-dichlorophenolindophenol (artificial electron acceptor) assay (23) . Interestingly, the specific activity of the recombinant rat/human hybrid PDH2 was only about 42% of that of the somatic human PDH1 and K m values for TPP and pyruvate were not changed. In contrast, our results show that purified recombinant human PDH2 and PDH1 have similar specific activities determined in PDC assay (Fig. 2, Table 1 ). We have constructed a new expression vector for PDH1 to have identical extension of the N-terminus of both the PDHs to avoid possible differences because of the different lengths of the extension at the N-termini. Kinetic parameters were not drastically different, however, K m for pyruvate was less for PDH2 (about 55%) compared to PDH1 when determined in the PDC assay. It is not known at the present time whether these small differences in the K m values for PDH2 have any physiological significance. Both PDH2 and PDH1 had similar thermostability at 37 0 C. PDH2 displayed the lag-phase in the progress curve of PDC reaction similar to that observed for PDH1, reflecting the activation of PDH during catalysis (32) . Our findings show that the two PDH isoenzymes have somewhat similar kinetic characteristics despite having differences of 47 amino acid residues between the α subunits of two PDH isoenzymes (87% identity).
As shown in Figure 3 , both PDH2 and PDH1 bind similarly to the PDH-binding domain of E2 as determined by SPR. Previously a similar approach was employed to study the interaction of PDH with the subunit-binding domain of E2 from Bacillus stearothermophilus (27) (27) compared to 17.5 nM and 42.5 nM for human PDH2 and PDH1, respectively). K D for PDH1 was 2.4-fold higher than for PDH2.
In PDH1 a single missense mutation causes a marked reduction in its activity (33) (34) (35) , then how can as many as 47 substitutions in the α subunit of PDH2 (94 per tetrameric α 2 β 2 ) not affect its catalytic activity? There are at least two examples of the residues in the sequence of PDH1 that are substituted in inherited PDH1 deficiency and are also substituted in PDH2 (i.e. H15 is substituted by tyrosine and F176 by alanine) (Fig. 1) . A patient having H15R mutation in PDH1 had only about 17% and 35% PDC activity at high concentrations of TPP in fibroblasts and cultured lymphoblasts, respectively, as compared to the corresponding control cells (38) . Purified recombinant PDH1 H15R mutant had only about 6% of the wild-type PDH1 specific activity and 2.8-fold higher apparent K m value for TPP (39) . The structure of human PDH1 revealed that H15 is involved in the organization of the N-terminus of the α subunit (40) . H15 forms hydrogen bonds with the neighboring residues, L17, D218 and G222. D218 in turn is bound to imino group of R16 (Fig. 7) . Substitution of H15 with arginine disrupts the interactions of D218 with residues at positions 15 and 16. Residues 218 and 222 belong to the loop region that is involved in the interaction with the neighboring α' subunit and residues of the TPP-motif (a structural motif participating in the binding of the pyrophosphate moiety of TPP through Mg 2+ ). Through a network of the interacting residues the substitution of H15, located far from the active site, could change the affinity for TPP. In PDH2 H15 is replaced with tyrosine. Interestingly, another two residues interacting with H15 in PDH1 are also replaced in PDH2, i.e. R16 with leucine and D218 with asparagine possibly causing some compensation in the structure. Replacement of R16 with a shorter residue may help to accommodate a bulkier tyrosine residue.
The second residue different between PDH1 and PDH2 sequences and replacement of which caused PDH1 deficiency is F176. Two patients with F176L mutation had decreased activity (about 25% of the control cells) and reduced amount of PDH1 protein (41, 42) . αF176 in the structure of PDH1 is close to α'F176 (3.7 Å distance between the rings), the same residue in the neighboring α' subunit (Fig. 7) . Interestingly, F176 is in the α-helix of the TPP-motif (residues 166-196 of PDH1 and PDH2) close to the residues interacting with the neighboring α' subunit. In PDH2 F176 is replaced with alanine which could probably fit in the space of phenylalanine, whereas substitution by leucine residue may disrupt the interaction between the α and α' subunits ( Fig. 7) and hence may destabilize the tetramer of PDH1.
The C-terminus of PDH1 α subunit interacts through the hydrogen bonding with amino acid residues of the β subunit which further interacts with specific residues in the β' subunit (40, 43) . Organization of the C-terminus of PDH1 is important as mutation PDH1 αR349H identified in 6 unrelated patients resulted in the decrease in activity and severe clinical manifestations (34) and recombinant mutant R349H of PDH1 had only about 1.2% of the wild-type PDC activity (32) . Sequential deletion of the C-terminal amino acid residues (from 361 to 358) decreased PDH1 activity as well as reduced the amount of the PDH1 protein expressed in a PDH-deficient cell line (44) . In PDH2 five residues in the C-terminal region of the α subunit (from 331 to 361) are replaced: P331, Y337, P344, P345 and Q353 in PDH1 are substituted by H331, H337, S344, S345, P353 in PDH2. Four of these substitutions involve proline residues that should cause a significant change in the conformation of the C-terminal region, and residue Q353 participates in the interaction with β subunit in PDH1 (30) . The organization of the C-terminus of PDH2 may be different from that of PDH1; however, how it compensates for these changes will only be known after the structure of PDH2 is determined.
The activity of PDC is regulated by a complex mechanism of phosphorylation/dephosphorylation (for reviews see (3, 15, 16) . We have analyzed the mutants with the substitutions of the phosphorylation sites to determine the mechanisms of inactivation of PDH2 by phosphorylation of its three sites. Phosphorylation of each of the three sites of PDH1 was suggested to cause inactivation by different mechanisms (11) . Apparently, that the possible mechanism of inactivation of PDH2 is similar to that of PDH1 based on the kinetic analyses of the alanine-and glutamate-substituted PDH2 mutants. Phosphorylation of site 1 in both the PDH2 and PDH1 probably affects the second catalytic step, i.e. the reductive acetylation of the lipoyl moieties of E2 and not the first decarboxylation step. A similar conclusion was made for the phosphorylation of the human branched-chain α-ketoacid dehydrogenase (45) . Structural analysis of the phosphorylation site 1 mutants indicated that phosphorylation of the branched-chain α-ketoacid dehydrogenase resulted in the conformational change preventing the lipoyl domain of the dihydrolipoamide succinyltransferase from binding. The affinity for TPP is decreased for the glutamate substitutions of sites 2 and 3 of PDH2. The PDH2-S1A mutant behaved differently than PDH1-S1A mutant in PDC reaction. PDH2-S1A had less activity and displayed inactivation during the reaction indicating possible involvement of Ser264 (site 1) of PDH2 in catalytic reaction.
Though the mechanisms of inactivation of the three sites of PDH2 seem to be similar to that for PDH1 inactivation, PDKs showed different activities towards the three phosphorylation sites of PDH2 than PDH1. Previously PDKs were shown to have different specificity for the three phosphorylation sites of human PDH1 (13) . The specificity of PDKs towards the three phosphorylation sites of PDH2 appeared to be similar to that of PDH1. However,, the activities of PDK1, PDK2, PDK4 but not PDK3 are lower for PDH2 than for PDH1. PDK3 is expressed predominantly in the testis with lower levels in lung, kidney and brain (14) . PDK2 is expressed in most of the tissues including testis (14) . PDK1 and PDK4 were not detected in testis (14) . Hence phosphorylation of PDH2 in the testis is carried out by PDK3 and PDK2 only. Since these two PDK isoenzymes phosphorylate sites 1 and 2 only (site 3 is phosphorylated only by PDK1), we suggest that site 3 in PDH2 is not subjected to phosphorylation in vivo in the testis.
The activities of PDP1 and PDP2 are also lower for PDH2 than PDH1 especially for site 2. PDPs are differentially expressed in different tissues. PDP1 was found to be present in most rat tissues with higher amounts in heart, brain and testis (19) . PDP2 was not detected in testis and was present primarily in heart, brain, liver and kidney (19) . Any differences in the structure of PDH2 compared to PDH1 may affect its interactions with PDK2, PDK3 and PDP1 in vivo and hence its regulation; however, this remains to be investigated. PDH2 is less efficiently phosphorylated as well as dephosphorylated than PDH1. It is difficult to predict the net result (whether the amount of PDH2 in the active form in the testis is different from that of PDH1) because of complexity of regulation and unknown comparative levels of expression of PDKs and PDPs in testis as well as in other tissues.
In summary, two isoenzymes of PDH have significant differences in the sequence (47 amino acid residues of α subunits of PDH2 and PDH1 are different resulting in 94 different amino acid residues of 1380 in α 2 β 2 tetramer). Nevertheless PDH2 is not significantly different from PDH1 in its kinetic characteristics and regulation. Examples of how two residues involved in PDH1-deficiency and substituted in PDH2 fit in the PDH1 structure without disturbing it are discussed above. How PDH2 compensates for the differences in its sequence will be known by comparison of the structure of human PDH1 with that of human PDH2 when it becomes available. Fig. 1 . Alignment of the amino acid sequences of the α subunits of human PDH2 and PDH1. Serines (S) of the three phosphorylation sites are shown in red and identified as sites 1 to 3 in red above serines. Nonidentical residues are in the colored boxes: yellow for homologous substitutions; orange for nonhomologous substitutions; pink for H15 and F176 of PDH1 replacement of which is known to cause PDH deficiency (38, 41, 42) ; and green for substitutions involving prolines in the C-terminal region. The TPPmotif sequences are underlined by a single line and the C-terminal region with multiple proline replacement is identified by doubled underlines. On the left hand side 's' designates somatic cell-specific PDH1 and 't' designates testis-specific PDH2. Fig. 2 . Activities of the wild-type PDH2, PDH2 phosphorylation site mutants and wild-type PDH1. Activities of PDHs were measured by the PDC assay following formation of NADH after reconstitution of PDHs with E2-BP and E3 in PDC. The results are means ± SE of 3 to 6 determinations; similar results were obtainded with 2-3 preparations of PDHs. * indicates undetectable activity. Activities of PDHs were measured by the PDC assay by formation of NADH after reconstitution of PDHs with E2-BP and E3 in PDC as described in the Experimental Procedures section.
FIGURE LEGENDS
Results are means ± SE of 2 to 5 independent determinations performed using 2-3 preparations of PDHs. ND, not determined due to inactivation of PDH2-S1A during the reaction and due to undetectable activity of PDH2-S1E. 
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